医学
贾纳斯激酶
特应性皮炎
Janus激酶抑制剂
危险分层
皮肤病科
内科学
细胞因子
作者
Shanthi Narla,Jonathan I. Silverberg
出处
期刊:Dermatitis
[Ovid Technologies (Wolters Kluwer)]
日期:2023-08-01
标识
DOI:10.1089/derm.2023.0058
摘要
Recently, 3 oral Janus kinase (JAK) inhibitors-abrocitinib, baricitinib, and upadacitinib-were approved in many regions around the world for the treatment of moderate-severe atopic dermatitis (AD). These JAK inhibitors generally have rapid onset of action and short half-life. Higher doses of abrocitinib and upadactinib even demonstrated superior efficacy to dupilumab. However, JAK inhibitors can be associated with rare serious and potentially life-threatening adverse events. Heterogeneity in study designs and lack of head-to-head studies make safety comparison between JAK inhibitors difficult. Dose reduction and patient selection are the most important considerations for risk mitigation. This narrative review examines the efficacy data for abrocitinib, baricitinib, and upadacitinib from large phase III double-blinded randomized controlled trials in AD and discusses risk stratification for oral JAK inhibitors in AD patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI